Catalog No.
DHG17601
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG4-kappa
Clonality
Monoclonal
Target
Leukocyte surface antigen CD47, CD47, Antigenic surface determinant protein OA3, IAP, Integrin-associated protein, Protein MER6, MER6
Concentration
3.65 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q08722
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
CD47, Hu5F9-G4, CAS: 2169232-81-7
Clone ID
Magrolimab
Final Results of a Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma., PMID:40485906
Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients With Acute Myeloid Leukaemia., PMID:40364806
Magrolimab Therapy in Conjunction with Conventional Chemotherapeutics Slows Disease Progression in Pediatric Acute Myeloid Leukemia Patient-Derived Xenograft Models., PMID:40361435
The ENHANCE-3 study: venetoclax and azacitidine plus magrolimab or placebo for untreated AML unfit for intensive therapy., PMID:40233321
Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis., PMID:40198272
A Phase 1b/2 Study of the Anti-CD47 Antibody Magrolimab with Cetuximab in Patients with Colorectal Cancer and Other Solid Tumors., PMID:40140179
Magrolimab plus azacitidine vs physician's choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 study., PMID:40009500
Macrophages as Potential Therapeutic Targets in Acute Myeloid Leukemia., PMID:39457618
Managing the unmanageable: evidence-driven approaches to real-world patient prototypes of TP53-mutant myelodysplastic neoplasms and acute myeloid leukemia., PMID:39349613
Magrolimab plus rituximab with or without chemotherapy in patients with relapsed/refractory diffuse large B-cell lymphoma., PMID:39293083
Circumventing resistance within the Ewing sarcoma microenvironment by combinatorial innate immunotherapy., PMID:39266215
Magrolimab plus rituximab in relapsed/refractory indolent non-Hodgkin lymphoma: 3-year follow-up of a phase 1/2 trial., PMID:39213421
Targeting the CD47/SIRPα pathway in malignancies: recent progress, difficulties and future perspectives., PMID:39040441
Combinatorial macrophage induced innate immunotherapy against Ewing sarcoma: Turning "Two Keys" simultaneously., PMID:38992659
Comparison of dose selection based on target engagement versus inhibition of receptor-ligand interaction for checkpoint inhibitors., PMID:38790133
TP53 Mutations in Acute Leukemias and Myelodysplastic Syndromes: Insights and Treatment Updates., PMID:38768424
How do transfusion services manage patients taking therapies such as anti-CD38 and anti-CD47 known to interfere with red blood cell compatibility testing?, PMID:38767410
Is drug interference still an issue for pretransfusion testing of patients on anti CD38 and other monoclonal antibody therapies?, PMID:38705581
Opportunities and challenges for anti-CD47 antibodies in hematological malignancies., PMID:38464520
Treatment outcomes of venetoclax-combination regimens for relapsed/refractory myeloid malignancies after anti-CD47-directed therapy., PMID:38441062
Transient red blood cell agglutination after Magrolimab administration in acute myeloid leukemia., PMID:38366740
Novel immunotherapies in the treatment of AML: is there hope?, PMID:38066884
Frontline treatment options for higher-risk MDS: can we move past azacitidine?, PMID:38066872
Transfusion management in the era of magrolimab (Hu5F9-G4), an anti-CD47 monoclonal antibody therapy., PMID:37970740
A humanized orthotopic mouse model for preclinical evaluation of immunotherapy in Ewing sarcoma., PMID:37868989
TP53-mutated acute myeloid leukemia and myelodysplastic syndrome: biology, treatment challenges, and upcoming approaches., PMID:37770618
Harnessing autologous immune effector mechanisms in acute myeloid leukemia: 2023 update of trials and tribulations., PMID:37729719
Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results., PMID:37703506
Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma)., PMID:37651261
Building on Foundations: Venetoclax-Based Combinations in the Treatment of Acute Myeloid Leukemia., PMID:37509251
Acute Myeloid Leukemia Treatment in the Elderly: A Comprehensive Review of the Present and Future., PMID:37459852
Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study., PMID:36888930
[Management of AML in the elderly]., PMID:36870810
Novel agents and regimens in acute myeloid leukemia: latest updates from 2022 ASH Annual Meeting., PMID:36869366
A phase II multi-arm study of magrolimab combinations in patients with relapsed/refractory multiple myeloma., PMID:36779512
The clinical impact of the molecular landscape of acute myeloid leukemia., PMID:36722402
An overview of novel therapies in advanced clinical testing for acute myeloid leukemia., PMID:36718500
Biological therapy in elderly patients with acute myeloid leukemia., PMID:36715330
Advances in myelodysplastic syndromes: promising novel agents and combination strategies., PMID:36620919
Dual checkpoint blockade of CD47 and LILRB1 enhances CD20 antibody-dependent phagocytosis of lymphoma cells by macrophages., PMID:36389667
Molecular targets for the treatment of AML in the forthcoming 5th World Health Organization Classification of Haematolymphoid Tumours., PMID:36271671
Updates on the Management of Acute Myeloid Leukemia., PMID:36230677
Current status of phase 3 clinical trials in high-risk myelodysplastic syndromes: pitfalls and recommendations., PMID:36215988
How I Treat TP53-Mutated Acute Myeloid Leukemia and Myelodysplastic Syndromes., PMID:36139679
Guidance for transfusion management in patients receiving magrolimab therapy (anti-CD47 monoclonal antibody)., PMID:36114660
Recent Advances in the Therapeutic Armamentarium of Acute Myeloid Leukemia: A Focus on the 63rd American Society of Hematology Annual Meeting Abstracts., PMID:36093823
Myeloid checkpoint blockade improves killing of T-acute lymphoblastic leukemia cells by an IgA2 variant of daratumumab., PMID:36052078
Follicular lymphoma: The long and winding road leading to your cure?, PMID:35908982
New Frontiers in Monoclonal Antibodies for the Targeted Therapy of Acute Myeloid Leukemia and Myelodysplastic Syndromes., PMID:35886899
Immune Checkpoint Inhibition in Acute Myeloid Leukemia and Myelodysplastic Syndromes., PMID:35883692
For research use only. Not for human or drug use.
